Hims & Hers Reports Q1 Loss Amid Expansion into Branded GLP-1 Drugs
Hims & Hers Health (HIMS) reported a net loss of $92.1 million for the first quarter, contrasting with expectations of profitability and causing its stock to drop nearly 14%. Despite revenue growth and subscriber increases, the company's shift toward branded GLP-1 drugs led to higher costs and reduced gross margins.
Tickers: $HIMS
Topics: GLP-1 drugs profitability stock performance telehealth